The Texas A&M Institute for Genomic Medicine (TIGM), a leading global source for genetic discoveries, has been selected by the Defense Threat Reduction Agency (DTRA) to identify and develop new drug targets for certain toxins, viruses and bacterial pathogens. By discovering and ultimately developing strategies to eliminate the ways in which toxins and microbes hijack cells, this research has the potential to discover new vaccines and therapies to counteract the most dangerous bio-threats faced by both military personnel and civilians.According to the press release, the award is for $12.25 M over 53 months.
The DTRA award will be used to develop first-in-class high-throughput screening procedures for mouse stem cells involving state-of-the-art robotic equipment and pioneering screening procedures. TIGM investigators will screen more than 3,500 different genes to identify those that enable toxins and microbes to injure cells and tissues. Once candidate genes are identified, TIGM researchers will develop therapies to be tested both in tissues and pre-clinical models.
Sunday, July 11, 2010
Testing toxins with TIGM
Last week, the TAMU News service announced